Your browser doesn't support javascript.
loading
Tumor mutational burden and immunotherapy in gliomas.
Merchant, Mythili; Ranjan, Alice; Pang, Ying; Yu, Guangyang; Kim, Olga; Khan, Javed; Wu, Jing.
Afiliación
  • Merchant M; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • Ranjan A; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • Pang Y; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • Yu G; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • Kim O; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • Khan J; Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • Wu J; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: jing.wu3@nih.gov.
Trends Cancer ; 7(12): 1054-1058, 2021 12.
Article en En | MEDLINE | ID: mdl-34580037
ABSTRACT
Tumor mutational burden (TMB) is an emerging biomarker for the prediction of immunotherapy success in solid tumors. Gliomas, however, do not demonstrate a correlation between TMB and immunotherapy efficacy. Here, we discuss the potential factors influencing this discordance, focusing on the impact of neoantigen immunogenicity, clonality, expression, and presentation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioma / Inmunoterapia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Trends Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioma / Inmunoterapia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Trends Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos